A detailed history of Tang Capital Management LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Tang Capital Management LLC holds 2,350,000 shares of CHRS stock, worth $2.59 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares
2,350,000
Previous 1,050,000 123.81%
Holding current value
$2.59 Million
Previous $1.82 Million 34.58%
% of portfolio
0.21%
Previous 0.22%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.99 - $1.8 $1.29 Million - $2.34 Million
1,300,000 Added 123.81%
2,350,000 $2.44 Million
Q2 2024

Aug 14, 2024

BUY
$1.58 - $2.51 $1.66 Million - $2.64 Million
1,050,000 New
1,050,000 $1.82 Million
Q2 2023

Aug 14, 2023

BUY
$3.79 - $8.3 $758,000 - $1.66 Million
200,000 Added 100.0%
400,000 $1.71 Million
Q1 2023

May 15, 2023

BUY
$5.89 - $10.52 $495,349 - $884,732
84,100 Added 72.56%
200,000 $1.37 Million
Q4 2022

Feb 14, 2023

SELL
$5.69 - $10.07 $3.61 Million - $6.39 Million
-634,100 Reduced 84.55%
115,900 $917,000
Q1 2022

May 16, 2022

BUY
$10.92 - $16.41 $1.09 Million - $1.64 Million
100,000 Added 15.38%
750,000 $9.68 Million
Q4 2020

Feb 16, 2021

BUY
$16.56 - $18.94 $1.66 Million - $1.89 Million
100,000 Added 18.18%
650,000 $11.3 Million
Q2 2020

Aug 14, 2020

BUY
$14.43 - $19.16 $2.89 Million - $3.83 Million
200,000 Added 57.14%
550,000 $9.82 Million
Q1 2020

May 15, 2020

BUY
$11.67 - $22.53 $4.08 Million - $7.89 Million
350,000 New
350,000 $5.68 Million

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $85.5M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Tang Capital Management LLC Portfolio

Follow Tang Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tang Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tang Capital Management LLC with notifications on news.